Bio-Techne Statistics
Total Valuation
Bio-Techne has a market cap or net worth of $11.33 billion. The enterprise value is $11.35 billion.
| Market Cap | 11.33B |
| Enterprise Value | 11.35B |
Important Dates
The last earnings date was Wednesday, August 12, 2026, before market open.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | Aug 24, 2026 |
Share Statistics
Bio-Techne has 156.82 million shares outstanding. The number of shares has decreased by -1.70% in one year.
| Current Share Class | 156.82M |
| Shares Outstanding | 156.82M |
| Shares Change (YoY) | -1.70% |
| Shares Change (QoQ) | -0.24% |
| Owned by Insiders (%) | 0.33% |
| Owned by Institutions (%) | 113.92% |
| Float | 156.17M |
Valuation Ratios
The trailing PE ratio is 62.28 and the forward PE ratio is 35.80.
| PE Ratio | 62.28 |
| Forward PE | 35.80 |
| PS Ratio | 9.32 |
| Forward PS | 8.97 |
| PB Ratio | 5.35 |
| P/TBV Ratio | 13.66 |
| P/FCF Ratio | 43.04 |
| P/OCF Ratio | 38.79 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 33.98, with an EV/FCF ratio of 43.13.
| EV / Earnings | 62.44 |
| EV / Sales | 9.34 |
| EV / EBITDA | 33.98 |
| EV / EBIT | 41.35 |
| EV / FCF | 43.13 |
Financial Position
The company has a current ratio of 4.55, with a Debt / Equity ratio of 0.14.
| Current Ratio | 4.55 |
| Quick Ratio | 2.94 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 0.81 |
| Debt / FCF | 1.10 |
| Interest Coverage | 28.51 |
Financial Efficiency
Return on equity (ROE) is 9.03% and return on invested capital (ROIC) is 9.66%.
| Return on Equity (ROE) | 9.03% |
| Return on Assets (ROA) | 6.67% |
| Return on Invested Capital (ROIC) | 9.66% |
| Return on Capital Employed (ROCE) | 11.33% |
| Weighted Average Cost of Capital (WACC) | 11.05% |
| Revenue Per Employee | $405,013 |
| Profits Per Employee | $60,613 |
| Employee Count | 3,000 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 2.13 |
Taxes
In the past 12 months, Bio-Techne has paid $58.82 million in taxes.
| Income Tax | 58.82M |
| Effective Tax Rate | 24.44% |
Stock Price Statistics
The stock price has increased by +33.36% in the last 52 weeks. The beta is 1.28, so Bio-Techne's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | +33.36% |
| 50-Day Moving Average | 71.93 |
| 200-Day Moving Average | 61.21 |
| Relative Strength Index (RSI) | 60.35 |
| Average Volume (20 Days) | 2,183,982 |
Short Selling Information
The latest short interest is 6.46 million, so 4.12% of the outstanding shares have been sold short.
| Short Interest | 6.46M |
| Short Previous Month | 9.28M |
| Short % of Shares Out | 4.12% |
| Short % of Float | 4.14% |
| Short Ratio (days to cover) | 1.85 |
Income Statement
In the last 12 months, Bio-Techne had revenue of $1.22 billion and earned $181.84 million in profits. Earnings per share was $1.16.
| Revenue | 1.22B |
| Gross Profit | 804.88M |
| Operating Income | 274.55M |
| Pretax Income | 240.68M |
| Net Income | 181.84M |
| EBITDA | 334.11M |
| EBIT | 274.55M |
| Earnings Per Share (EPS) | $1.16 |
Balance Sheet
The company has $265.48 million in cash and $289.09 million in debt, with a net cash position of -$23.61 million or -$0.15 per share.
| Cash & Cash Equivalents | 265.48M |
| Total Debt | 289.09M |
| Net Cash | -23.61M |
| Net Cash Per Share | -$0.15 |
| Equity (Book Value) | 2.11B |
| Book Value Per Share | 13.51 |
| Working Capital | 580.70M |
Cash Flow
In the last 12 months, operating cash flow was $292.07 million and capital expenditures -$28.85 million, giving a free cash flow of $263.22 million.
| Operating Cash Flow | 292.07M |
| Capital Expenditures | -28.85M |
| Depreciation & Amortization | 59.56M |
| Net Borrowing | -146.00M |
| Free Cash Flow | 263.22M |
| FCF Per Share | $1.68 |
Margins
Gross margin is 66.24%, with operating and profit margins of 22.60% and 14.97%.
| Gross Margin | 66.24% |
| Operating Margin | 22.60% |
| Pretax Margin | 19.81% |
| Profit Margin | 14.97% |
| EBITDA Margin | 27.50% |
| EBIT Margin | 22.60% |
| FCF Margin | 21.66% |
Dividends & Yields
This stock pays an annual dividend of $0.32, which amounts to a dividend yield of 0.44%.
| Dividend Per Share | $0.32 |
| Dividend Yield | 0.44% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 27.59% |
| Buyback Yield | 1.70% |
| Shareholder Yield | 2.14% |
| Earnings Yield | 1.60% |
| FCF Yield | 2.32% |
Analyst Forecast
The average price target for Bio-Techne is $70.73, which is -2.10% lower than the current price. The consensus rating is "Hold".
| Price Target | $70.73 |
| Price Target Difference | -2.10% |
| Analyst Consensus | Hold |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 8.24% |
| EPS Growth Forecast (3Y) | 9.78% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 30, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Nov 30, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
Bio-Techne has an Altman Z-Score of 12.89 and a Piotroski F-Score of 7.
| Altman Z-Score | 12.89 |
| Piotroski F-Score | 7 |